Role of NIB in connecting science to patients by assuring safe and quality anti diabetic products

  • Gurminder Bindra Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh
  • Charu Mehra Kamal Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh
  • Meena Kumari Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh
  • Sanjay Mendiratta Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh
  • Preety Sharma Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh
  • Surinder Singh National Institute of Biologicals, NOIDA
Keywords: Insulin Lispro, Indian Pharmacopocia (Ip), National Institute of Biologicals (NIB)

Abstract

In India burden of diabetes is increasing and expected to cross the 100 million mark by 2030. Therefore, the development of national policies for the prevention, treatment, and care of diabetes in line with the sustainable development of health care systems is the need of the hour. National Institute of Biologicals (NIB) responsibly assures and reviews the quality of Biological products to the end users by weeding out “Not-of-Standard-Quality” Biological Medicines from reaching Indian market,   thereby safeguarding the Public Health by testing at our state-of-art-laboratory. NIB receives samples from various sources such as State Port offices, Central Drug Standard Control Organization (CDSCO), Stakeholders of biotherapeutic manufacturers, legal & global tender samples. They are tested by pharmacopoeial methods or manufacturer’s method for Key Quality Attributes (KQA). The heterogeneity of products involves human recombinant biotherapeutic Insulin, Insulin Analogues, and Peptides of nearly 20 different types eg. Biphasic Insulin, Glargine, Aspart, Exenatide, Liraglutide, etc. which have their global presence for the antidiabetic patient care. Testing for quality attributes such as Identification, Potency, Purity, Stability, Related Impurity and Safety parameters along with the physiochemical test is carried out to ensure the safety, quality, and effectiveness of the product.  In addition, reference standards are also being developed at NIB which serves as the measurement standards and complements the written standards in India pharmacopeia. All the testing is carried out strictly adhering to the timelines so that the quality product is delivered to meet the ever-growing public health challenge

NIB maintains quality systems of ISO 17025 standards for continuous improvement, function as Central Drugs Laboratory(CDL). It focuses on a continuous supply of lifesaving biotherapeutics to ensure the success of the Non-Communicable Disease (NCD) programme for Diabetes.

Author Biographies

Gurminder Bindra, Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh

M.Sc., SCIENTIST-III 

Charu Mehra Kamal, Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh

Ph.D., Head of Lab & Scientist Grade II

Meena Kumari, Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh

Ph.D., Scientist Grade III

Sanjay Mendiratta, Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh

Ph.D., Junior Scientist 

Preety Sharma, Recombinant Product Laboratory, National Institute of Biologicals, A-32, Sector 62, NOIDA, 201309 Uttar Pradesh

M.Sc., Biologist

Surinder Singh, National Institute of Biologicals, NOIDA

M.D., Director

References

1. Malik R “India is the diabetic capital of the world” The Times of India, 2016 Jan , https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/India-is-the-diabetes-capital-of-the-world/articleshow/50753461.cms
2. Kumar KMP, Banshi S, Rao PV, Sarda A, Vishwanathan V, Kalra S , Sethi B, Shah N, Srikanta SSS, Jain SM, et al. “Type 1 diabetes: Awareness, management and challenges: Current scenario in India”. Indian Journal of Endocrinology and metabolism 2015, 19:S6-S8.
3. National Institute of Biologicals.www.nib.gov.in. Accessed on October 201 7
4. Insulin basics. American Diabetes Association website. Last edited 2015
5. Guidance document, Recombinant Products laboratory, NIB. 12 sept 2013 http://www.nib.gov.in/guidance_document/RPL_Guidance_Document-Revised_12Sep2013.pdf
6. Moorkens E. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. “Strategies of players on the global biopharmaceutical market” GaBI: 2017; Sept . (http://gabionline.net/Biosimilars/Research/Strategies-of-players-on-the-global-biopharmaceutical-market).
7. Williams R L, Bristow A F, Hauck W W, Srinivasan V S ,Morris T, Atouf F, Ambrose M,Surendranath K V, Chakrabarty R and Menon K: “Role of public standards in the Safety and Efficacy of biologic Medicines”. AAPS Journal May 2014, Volume 16, , pp 516–521
Published
2019-05-27
How to Cite
1.
Bindra G, Kamal CM, Kumari M, Mendiratta S, Sharma P, Singh S. Role of NIB in connecting science to patients by assuring safe and quality anti diabetic products. jms [Internet]. 2019May27 [cited 2019Jul.19];22(1):16-0. Available from: http://jmsskims.org/index.php/jms/article/view/445
Section
Mini Review